TY - JOUR
T1 - Implications of Sphingolipid Metabolites in Kidney Diseases
AU - Mallela, Shamroop Kumar
AU - Merscher, Sandra
AU - Fornoni, Alessia
N1 - Funding Information:
This project was supported by grants from National Institutes of Health (grant numbers R01DK117599, R01DK104753 and R01CA227493) to A.F. and S.M., and the Miami Clinical Translational Science Institute (grant numbers U54DK083912, UM1DK100846, U01DK116101 and UL1TR000460) to A.F.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Sphingolipids, which act as a bioactive signaling molecules, are involved in several cellular processes such as cell survival, proliferation, migration and apoptosis. An imbalance in the levels of sphingolipids can be lethal to cells. Abnormalities in the levels of sphingolipids are associated with several human diseases including kidney diseases. Several studies demonstrate that sphingolipids play an important role in maintaining proper renal function. Sphingolipids can alter the glomerular filtration barrier by affecting the functioning of podocytes, which are key cellular components of the glomerular filtration barrier. This review summarizes the studies in our understanding of the regulation of sphingolipid signaling in kidney diseases, especially in glomerular and tubulointerstitial diseases, and the potential to target sphingolipid pathways in developing therapeutics for the treatment of renal diseases.
AB - Sphingolipids, which act as a bioactive signaling molecules, are involved in several cellular processes such as cell survival, proliferation, migration and apoptosis. An imbalance in the levels of sphingolipids can be lethal to cells. Abnormalities in the levels of sphingolipids are associated with several human diseases including kidney diseases. Several studies demonstrate that sphingolipids play an important role in maintaining proper renal function. Sphingolipids can alter the glomerular filtration barrier by affecting the functioning of podocytes, which are key cellular components of the glomerular filtration barrier. This review summarizes the studies in our understanding of the regulation of sphingolipid signaling in kidney diseases, especially in glomerular and tubulointerstitial diseases, and the potential to target sphingolipid pathways in developing therapeutics for the treatment of renal diseases.
KW - glomerular diseases
KW - sphingolipids
KW - tubulointerstitial diseases
UR - http://www.scopus.com/inward/record.url?scp=85127881843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127881843&partnerID=8YFLogxK
U2 - 10.3390/ijms23084244
DO - 10.3390/ijms23084244
M3 - Review article
AN - SCOPUS:85127881843
VL - 23
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 8
M1 - 4244
ER -